AIGH Capital Management LLC Acquires Shares of 1,715,000 Personalis, Inc. $PSNL

AIGH Capital Management LLC acquired a new stake in Personalis, Inc. (NASDAQ:PSNL - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,715,000 shares of the company's stock, valued at approximately $22,981,000. Personalis makes up 1.4% of AIGH Capital Management LLC's holdings, making the stock its 12th biggest holding. AIGH Capital Management LLC owned 1.64% of Personalis as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Bank of New York Mellon Corp acquired a new stake in Personalis in the 2nd quarter valued at $2,533,000. GSA Capital Partners LLP purchased a new position in Personalis during the second quarter valued at $579,000. Bank of America Corp DE grew its position in shares of Personalis by 85.4% in the first quarter. Bank of America Corp DE now owns 111,306 shares of the company's stock valued at $709,000 after purchasing an additional 51,273 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of Personalis in the first quarter valued at about $192,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Personalis during the first quarter worth about $159,000. 61.91% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Personalis

In other news, CFO Aaron Tachibana sold 51,251 shares of the stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $13.18, for a total value of $675,488.18. Following the completion of the sale, the chief financial officer owned 198,833 shares of the company's stock, valued at $2,620,618.94. This represents a 20.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the firm's stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $13.15, for a total transaction of $1,315,000.00. Following the sale, the chief executive officer owned 235,986 shares of the company's stock, valued at $3,103,215.90. This represents a 29.76% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 435,032 shares of company stock worth $5,599,929 over the last ninety days. 4.20% of the stock is owned by insiders.

Personalis Price Performance

Shares of PSNL opened at $14.04 on Monday. Personalis, Inc. has a 52-week low of $4.44 and a 52-week high of $16.39. The stock has a fifty day simple moving average of $12.69 and a two-hundred day simple moving average of $9.47. The company has a market capitalization of $1.47 billion, a PE ratio of -12.88 and a beta of 2.27.

Personalis (NASDAQ:PSNL - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. The firm had revenue of $22.36 million for the quarter, compared to analyst estimates of $16.69 million. As a group, equities analysts anticipate that Personalis, Inc. will post -1.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on PSNL. Morgan Stanley boosted their price objective on Personalis from $9.00 to $13.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 9th. Lake Street Capital lowered Personalis from a "buy" rating to a "hold" rating and set a $16.25 price target on the stock. in a research note on Monday, July 20th. Weiss Ratings restated a "sell (d-)" rating on shares of Personalis in a report on Friday, July 17th. BTIG Research lifted their target price on shares of Personalis from $11.00 to $16.25 and gave the stock a "buy" rating in a research note on Monday, July 20th. Finally, Wall Street Zen cut shares of Personalis from a "hold" rating to a "sell" rating in a research report on Saturday, June 13th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Personalis presently has an average rating of "Hold" and an average price target of $14.25.

Personalis Profile

Personalis, Inc NASDAQ: PSNL is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source